J-P Foy1,2,3, C Bertolus3, M-C Michallet1, S Deneuve4, R Incitti5, N Bendriss-Vermare1, M-A Albaret1,5, S Ortiz-Cuaran1,5, E Thomas5, A Colombe2, C Py6, N Gadot2, J-P Michot6, J Fayette7, A Viari5, B Van den Eynde8, P Goudot3, M Devouassoux-Shisheboran9, A Puisieux1, C Caux1, P Zrounba4, S Lantuejoul2,6, P Saintigny1,2,7. 1. Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, 69008. 2. Department of Translational Research and Innovation, Centre Léon Bérard. 3. Department of Oral and Maxillo-Facial Surgery, University of Paris 6, Pitié-Salpêtriére Hospital, Paris. 4. Department of Surgery, Centre Léon Bérard. 5. Synergie Lyon Cancer-Platform of Bioinformatics-Gilles Thomas, Centre Léon Bérard. 6. Department of Biopathology, Centre Léon Bérard. 7. Department of Medicine, Centre Léon Bérard, France. 8. Ludwig Institute for Cancer Research, Brussels Branch and de Duve Institute, Université catholique de Louvain, B-1200, Brussels, Belgium. 9. Department of Pathology, Croix-Rousse Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France.
Abstract
BACKGROUND: Never-smokers and never-drinkers patients (NSND) suffering from oral squamous cell carcinoma (OSCC) are epidemiologically different from smokers drinkers (SD). We therefore hypothesized that they harbored distinct targetable molecular alterations. PATIENTS AND METHODS: Data from The Cancer Genome Atlas (TCGA) (discovery set), Gene Expression Omnibus and Centre Léon Bérard (CLB) (three validation sets) with available gene expression profiles of HPV-negative OSCC from NSND and SD were mined. Protein expression profiles and genomic alterations were also analyzed from TCGA, and a functional pathway enrichment analysis was carried out. Formalin-fixed paraffin-embedded samples from 44 OSCC including 20 NSND and 24 SD treated at CLB were retrospectively collected to perform targeted-sequencing of 2559 transcripts (HTG EdgeSeq system), and CD3, CD4, CD8, IDO1, and PD-L1 expression analyses by immunohistochemistry (IHC). Enrichment of a six-gene interferon-γ signature of clinical response to pembrozulimab (PD-1 inhibitor) was evaluated in each sample from all cohorts, using the single sample gene set enrichment analysis method. RESULTS: A total of 854 genes and 29 proteins were found to be differentially expressed between NSND and SD in TCGA. Functional pathway analysis highlighted an overall enrichment for immune-related pathways in OSCC from NSND, especially involving T-cell activation. Interferon-γ response and PD1 signaling were strongly enriched in NSND. IDO1 and PD-L1 were overexpressed and the score of response to pembrolizumab was higher in NSND than in SD, although the mutational load was lower in NSND. IHC analyses in the CLB cohort evidenced IDO1 and PD-L1 overexpression in tumor cells that was associated with a higher rate of tumor-infiltrating T-cells in NSND compared with SD. CONCLUSION: The main biological and actionable difference between OSCC from NSND and SD lies in the immune microenvironment, suggesting a higher clinical benefit of PD-L1 and IDO1 inhibition in OSCC from NSND.
BACKGROUND: Never-smokers and never-drinkers patients (NSND) suffering from oral squamous cell carcinoma (OSCC) are epidemiologically different from smokers drinkers (SD). We therefore hypothesized that they harbored distinct targetable molecular alterations. PATIENTS AND METHODS: Data from The Cancer Genome Atlas (TCGA) (discovery set), Gene Expression Omnibus and Centre Léon Bérard (CLB) (three validation sets) with available gene expression profiles of HPV-negative OSCC from NSND and SD were mined. Protein expression profiles and genomic alterations were also analyzed from TCGA, and a functional pathway enrichment analysis was carried out. Formalin-fixed paraffin-embedded samples from 44 OSCC including 20 NSND and 24 SD treated at CLB were retrospectively collected to perform targeted-sequencing of 2559 transcripts (HTG EdgeSeq system), and CD3, CD4, CD8, IDO1, and PD-L1 expression analyses by immunohistochemistry (IHC). Enrichment of a six-gene interferon-γ signature of clinical response to pembrozulimab (PD-1 inhibitor) was evaluated in each sample from all cohorts, using the single sample gene set enrichment analysis method. RESULTS: A total of 854 genes and 29 proteins were found to be differentially expressed between NSND and SD in TCGA. Functional pathway analysis highlighted an overall enrichment for immune-related pathways in OSCC from NSND, especially involving T-cell activation. Interferon-γ response and PD1 signaling were strongly enriched in NSND. IDO1 and PD-L1 were overexpressed and the score of response to pembrolizumab was higher in NSND than in SD, although the mutational load was lower in NSND. IHC analyses in the CLB cohort evidenced IDO1 and PD-L1 overexpression in tumor cells that was associated with a higher rate of tumor-infiltrating T-cells in NSND compared with SD. CONCLUSION: The main biological and actionable difference between OSCC from NSND and SD lies in the immune microenvironment, suggesting a higher clinical benefit of PD-L1 and IDO1 inhibition in OSCC from NSND.
Authors: Jean-Philippe Foy; Chloé Bertolus; David Boutolleau; Henri Agut; Antoine Gessain; Zdenko Herceg; Pierre Saintigny Journal: Front Oncol Date: 2020-05-21 Impact factor: 6.244
Authors: Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio Journal: Cell Prolif Date: 2018-11-15 Impact factor: 6.831
Authors: Kyriakos Chatzopoulos; Sotiris Sotiriou; Andrea R Collins; Panagiotis Kartsidis; Alessandra C Schmitt; Xianfeng Chen; Khashayarsha Khazaie; Michael L Hinni; Colleen A Ramsower; Matthew A Zarka; Samir H Patel; Joaquin J Garcia Journal: Head Neck Pathol Date: 2020-10-03
Authors: Manuel Olmos; Jacek Glajzer; Tjark-Ole Büntemeyer; Gesche Frohwitter; Jutta Ries; Markus Eckstein; Markus Hecht; Rainer Lutz; Marco Rainer Kesting; Manuel Weber Journal: Front Oncol Date: 2021-07-21 Impact factor: 6.244